Oral Estradiol for Transgender HRT: Long-Term Follow-Up Findings

What "Off-Label" Means Here, and Why It Matters

Oral estradiol tablets (17-beta-estradiol, sold as Estrace and generic equivalents) are FDA-approved for treatment of moderate-to-severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis, and hypoestrogenism caused by surgical castration or primary ovarian insufficiency in cisgender women. Prescribing for transgender women's feminizing hormone therapy is explicitly off-label, meaning no randomized controlled trial submitted to the FDA was specifically designed for this population.

Off-label prescribing is legal and clinically common. The Endocrine Society, UCSF, and WPATH all publish practice guidelines supporting its use. Still, every woman reading this article, cisgender or transgender, deserves to know when evidence is extrapolated from one population and applied to another.

The evidence gap is real. Most long-term follow-up studies on feminizing HRT enrolled fewer than 1,000 participants and were retrospective. A 2019 systematic review by Trum et al. Identified only 14 longitudinal studies on transgender women's health outcomes with follow-up exceeding two years, and none were randomized. This is the baseline from which all risk-benefit conversations must start.

How Oral Estradiol Works in Feminizing HRT

The pharmacokinetics of the oral route

When you swallow estradiol, it undergoes first-pass hepatic metabolism. Roughly 95 percent is converted to estrone before reaching systemic circulation, producing a serum estrone-to-estradiol ratio of approximately 5:1. This ratio is clinically relevant because estrone is a weaker estrogen but also drives more hepatic protein synthesis, including coagulation factors and sex hormone-binding globulin. The net effect is a pro-coagulant shift that does not occur, or occurs far less, with transdermal delivery.

Peak serum estradiol after a single 2 mg oral dose is typically 50-100 pg/mL, falling to baseline within 8-12 hours. This fluctuation is one reason some clinicians split daily doses (e.g., 2 mg twice daily rather than 4 mg once daily) to smooth the pharmacokinetic curve.

Why the liver sees everything first

The first-pass effect also raises HDL cholesterol and lowers LDL, which looks favorable on a lipid panel. It is not an unambiguous benefit, however. The same hepatic stimulation elevates C-reactive protein and triglycerides and may reduce antithrombin III. A 2013 pharmacokinetic analysis by Gomes et al. Confirmed that oral, but not transdermal, estradiol significantly increases triglycerides and CRP in transgender women. Triglyceride elevation matters particularly if you have pre-existing hypertriglyceridemia or metabolic syndrome.

Dosing Across the Feminizing HRT Timeline

Starting doses and titration

The Endocrine Society 2017 guidelines recommend starting oral estradiol at 2 mg daily and titrating every 3 months to a target serum level of 100-200 pg/mL, measured as a trough (morning, before the day's dose). Maximum doses in clinical practice typically run 8 mg daily in divided doses, though some individuals with intact gonads may require more suppression and their clinicians add an antiandrogen rather than pushing estradiol higher.

Post-orchiectomy, estrogen requirements generally drop because testicular testosterone production ceases. UCSF's Transgender Care guidelines note that many post-orchiectomy patients maintain adequate serum levels on 2-4 mg daily, reducing cumulative exposure and associated risks.

Dose and life stage

Younger transgender women (teens through mid-30s) on intact gonadal function typically need higher doses to suppress testosterone adequately. Those over 50, especially post-orchiectomy, have a risk profile closer to cisgender postmenopausal women on HRT, where cardiovascular and thrombotic considerations become primary. The British Society for Sexual Medicine and WPATH both emphasize individualized dosing rather than a fixed ceiling.

Long-Term Cardiovascular Findings

VTE: the most documented long-term risk

The association between oral estradiol and venous thromboembolism (VTE) in transgender women is the most consistently replicated finding in the literature. The Amsterdam cohort study by Asscheman et al., following 966 transgender women over a mean of 18.5 years, found a VTE incidence of 6.3 per 1,000 person-years, compared with 1.0 per 1,000 in the cisgender male reference population. That is a roughly six-fold higher rate, most of which occurred in those using oral rather than transdermal estradiol or ethinyl estradiol.

A 2019 retrospective cohort from the Veterans Affairs system (Alzahrani et al.) confirmed elevated VTE risk in transgender women compared with cisgender controls, with an adjusted odds ratio of 4.5 (95% CI 2.0-10.0).

Risk is higher if you smoke, have a personal or family history of clotting disorders, have a BMI above 30, or are over 40. Thrombophilia screening before starting oral estradiol is recommended but not universally performed. The Endocrine Society recommends it in individuals with personal or family history of unprovoked VTE.

Stroke and arterial events

The picture for stroke is less clear. The Amsterdam cohort found a non-significant trend toward increased ischemic stroke risk; a later analysis of the same cohort published in 2014 by Asscheman et al. Found standardized mortality ratios for cardiovascular disease higher than expected. The 2021 analysis by Getahun et al. In the Annals of Internal Medicine, using Kaiser Permanente data from 2,842 transgender women, found stroke incidence of 4.1 per 1,000 person-years compared with 1.5 in cisgender men and 1.7 in cisgender women, though route of administration was incompletely captured.

Whether oral versus transdermal estradiol specifically drives arterial risk remains an open question. Confounders including baseline cardiovascular risk, smoking, and use of older synthetic estrogens (ethinyl estradiol, now largely abandoned) complicate older datasets.

Lipid effects: a mixed picture

Oral estradiol consistently raises HDL and lowers LDL in transgender women. A 2020 meta-analysis by Irwig in Andrology pooled 12 studies and found mean HDL increase of 9.5 mg/dL and LDL decrease of 16 mg/dL with estrogen-based feminizing therapy, predominantly using oral routes. Triglycerides rose by a mean of 27 mg/dL in the same analysis. Whether the net lipid effect translates into a clinical cardiovascular benefit long-term has not been demonstrated in transgender-specific outcomes data.

Long-Term Bone Health Findings

Oral estradiol preserves and, in many cases, increases bone mineral density in transgender women. This is one of the clearest long-term benefits in the literature.

A 2018 cohort study by Singh-Ospina et al. Examining 82 transgender women over a median of 4.4 years found lumbar spine BMD Z-scores improved from a mean of -0.3 to +0.4, with femoral neck BMD remaining stable. Bone benefit appears dose-dependent and is greatest in those who achieve target serum estradiol levels consistently.

The clinical concern is what happens if HRT is stopped. Like cisgender postmenopausal women who discontinue estrogen, transgender women who stop estradiol (without orchiectomy) may see accelerated bone loss. Post-orchiectomy, endogenous estrogen is absent entirely, making lifelong therapy or alternative bone protection strategies a real clinical conversation.

A practical framework for bone monitoring in transgender women on oral estradiol:

• Baseline DEXA: before or within 1 year of starting HRT, especially if prior prolonged testosterone suppression or low vitamin D
• Repeat DEXA at 2 years: to confirm trajectory, especially in those with baseline low BMD or suboptimal estradiol levels
• Supplement vitamin D and calcium: same targets as cisgender women at risk for osteoporosis (vitamin D 1,500-2,000 IU daily, calcium 1,000-1,200 mg daily from diet plus supplement)
• Consider bisphosphonate if BMD remains below -2.5 T-score despite adequate estradiol levels and supplementation

Long-Term Cancer Risk Findings

Breast cancer

Transgender women on long-term feminizing HRT have a breast cancer risk higher than cisgender men but lower than cisgender women, based on available data. The largest study to date, a 2019 analysis of Dutch registry data by de Blok et al. (n=2,260 transgender women, median follow-up 18 years), found a breast cancer incidence of 4.1 per 100,000 person-years, which is higher than cisgender men but lower than cisgender women aged 50-74. That same paper found 15 cases of breast cancer in transgender women, with the first case appearing after 8 years of HRT.

Screening guidance is evolving. ACOG currently recommends individualized breast cancer screening discussions for transgender women, noting that those who have used estrogen for 5 or more years and are over 50 may benefit from mammography. Clinical breast exams remain appropriate regardless of age.

Prostate cancer

Prostate cancer risk appears reduced with long-term estrogen exposure, but the prostate does not disappear with feminizing HRT. The Amsterdam cohort found only two prostate cancer diagnoses in 1,833 transgender women over a mean follow-up of 18 years, far below what would be expected in cisgender men of the same age. PSA testing in transgender women is complicated because estrogen suppresses PSA; a "normal" PSA in a transgender woman may actually represent significant prostate pathology if not interpreted in context.

Pregnancy, Lactation, and Contraception Considerations

This section is required for every drug article at WomanRx and is not omitted here.

Pregnancy: Oral estradiol is classified FDA Pregnancy Category X for use in persons with a uterus because of the risk to a developing fetus. Transgender women (assigned male at birth) do not have a uterus or ovaries and cannot become pregnant. This specific category X concern does not apply to them directly.

Fertility preservation: Feminizing HRT, including oral estradiol, suppresses spermatogenesis. A 2018 systematic review by Hamada et al. Found that sperm production may be severely impaired or absent after as few as 6 months of estrogen therapy, and the effect may not be fully reversible after long-term use. Any transgender woman who has not had orchiectomy and wishes to preserve fertility should bank sperm before starting HRT. This is a time-sensitive conversation, not one to defer.

Lactation: The question of lactation is relevant for transgender women who wish to nurse. Small case series, including one reported in Transgender Health in 2018 by Reisman and Goldstein, document induced lactation in transgender women using a protocol of domperidone, breast stimulation, and estradiol. Data on milk composition, infant safety, and adequacy of nutrition are extremely limited. If a transgender woman chooses to attempt nursing while on estradiol, this should be done in close consultation with a lactation specialist and pediatrician.

Contraception: Transgender women on estradiol do not require contraception for pregnancy prevention (they cannot conceive). If a transgender woman has sex with a partner who could conceive, contraception for that partner is the relevant consideration.

Who This Is Right For, and Who Should Think Carefully

Life stages where oral estradiol may be appropriate

Oral estradiol is a reasonable first-line option for transgender women who are younger than 45, do not smoke, have no personal or family history of VTE, have a BMI below 30, and have no significant cardiovascular disease. The convenience of a pill, wide availability, and low cost make it accessible.

When to reconsider oral and discuss transdermal instead

You should have an explicit conversation with your clinician about switching to transdermal estradiol if any of the following apply:

• Personal or family history of DVT or pulmonary embolism
• Inherited thrombophilia (Factor V Leiden, prothrombin mutation, protein C or S deficiency)
• Active smoking or stopping within the last year
• BMI above 30
• Age over 45 with additional cardiovascular risk factors
• Migraine with aura (associated with stroke risk, and estrogen fluctuation may worsen it)
• Hypertriglyceridemia (transdermal avoids first-pass triglyceride elevation)

The 2017 Endocrine Society guidelines explicitly recommend considering transdermal estradiol for transgender women at elevated VTE risk, though they do not mandate it.

Post-orchiectomy dosing reconsideration

After orchiectomy, testosterone suppression by an antiandrogen is no longer needed, and estradiol doses can often be reduced. This is clinically significant because lower cumulative estradiol dose reduces long-term VTE and cardiovascular exposure. A reassessment appointment within 3 months of orchiectomy is the standard of care at most gender-affirming clinics.

Monitoring: What Long-Term Follow-Up Actually Looks Like

Based on Endocrine Society 2017 guidelines and UCSF Transgender Care protocols, monitoring for a transgender woman on oral estradiol should follow this schedule:

Every 3 months for the first year:

• Serum estradiol (trough, before morning dose)
• Serum testosterone (to confirm suppression below 50 ng/dL if antiandrogen is used)
• Basic metabolic panel
• Blood pressure

Every 6-12 months thereafter:

• Fasting lipid panel
• Hemoglobin A1c (if BMI above 25 or family history of diabetes)
• Liver function tests (especially with higher oral doses)
• Weight and BMI

At baseline and every 2 years:

• DEXA scan if risk factors for osteoporosis are present
• Breast exam (and consider mammography after 5 years of therapy and age 50+)

ACOG's 2021 Committee Opinion on transgender care states that all clinicians providing primary care to transgender patients should be prepared to perform routine health maintenance, not just HRT management. Pap smear guidance, STI screening, and mental health support are part of comprehensive care.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in clinical trials. Transgender women have been even more so. The data we have are almost entirely from retrospective cohort studies, many European, and most conducted before transdermal estradiol became a clinical standard of care. Older studies used ethinyl estradiol (no longer recommended because of its sharply higher VTE risk) and conjugated equine estrogens, making comparison to current practice difficult.

The STRONG (Study of Transition, Outcomes, and Gender) cohort, published by Getahun et al. In 2018 in JAMA Internal Medicine, is the largest US-based transgender health outcomes study to date with over 3,800 transgender women, but even this study could not isolate oral versus transdermal estradiol effects on cardiovascular outcomes.

Specific gaps that matter clinically:

• No long-term randomized data comparing oral versus transdermal estradiol in transgender women for cardiovascular outcomes
• No prospective data on breast cancer risk stratified by duration and dose
• Limited data in transgender women over 65
• No data on how race and ethnicity modify long-term risk (most cohorts are predominantly white European)

The honest answer is that many recommendations are extrapolated from cisgender postmenopausal women's HRT data. That extrapolation may be reasonable on a physiological basis but has not been validated prospectively in transgender populations.

Direct Quotations from Guidelines

"Hormone therapy should be tailored to the individual's goals, with consideration of the risks associated with the route of administration." Endocrine Society Clinical Practice Guideline, 2017.

"Clinicians should discuss the risks of venous thromboembolism with all patients considering oral estrogen and should consider transdermal routes in those with elevated baseline risk." Endocrine Society Clinical Practice Guideline, 2017.